Ananda Pharma Announcements

JP Morgan HealthcareWeek is the largest annual gathering in the global healthcare industry. Ittakes place every January in San Francisco alongside the JP Morgan HealthcareConference and attracts more than 100,000 attendees each year. Participantsrange from large pharmaceutical companiesto emerging biotechs like Ananda, all focused on buildingrelationships and exploring dealmaking opportunities.  

The week is widelyseen as setting the tone for the healthcare year ahead, so hopping on the planeto go and represent Ananda made for an exciting start to 2026. The moodwas positive, and almost everyone I spoke to commented on the increasedlevel of activity and interest compared with the past 2-3 years. 

A recurring topicacross many conversations was the patent cliff facing large pharmaceuticalcompanies, with many major drugs expected to face genericcompetition in the near future. As a result, these companies are activelyseeking partnerships, acquisitions, and investment opportunities to strengthentheir future pipelines. This creates a strong opportunityfor biotechs like Ananda that can position themselves in areas ofunmet need and sizeable markets. It was particularly encouraging to hear theclear preference for drugs with a shorter timeline to market, which aligns wellwith Ananda’s strengths. 

Over the course of theweek, I met with several potential investors and pharmaceutical companies.These discussions provided an opportunity to present Ananda’spipeline, progress to date, and our main milestones over the next 12-18 months.We also discussed potential partnerships, market needs, and what investors andcompanies are prioritising over the coming year. 

A consistent theme wasthe focus among larger companies on robust clinical trial data and measurableoutcomes, rather than earlier-stage research alone. While early research canoffer greater upside, it also carries more uncertainty and is further from commercialisation.Hearing this repeated across meetings was a welcome validation of Ananda’sstrategy. 

Most investors I spokewith welcomed the improving sentiment across the sector, particularly the morepositive outlook for exits through IPOs, licensing deals, and acquisitions bylarge pharmaceutical companies. Only a few weeks later, this was reflected inmarket activity, with eight US IPOs in the first week of February, four ofwhich were biotech companies. This aligns with what was discussed during theweek and suggests momentum is building, which is great to see.  

I attended two women’shealth events, as well as several sessions focused on the practical use ofartificial intelligence in healthcare. These are areas Ananda is activelyexploring, so it was great to hear directly from those working at theforefront. I was also thrilled to meet face-to-face with severalpotential service providers to support our plans in the US market. Thesediscussions helped build a clearer picture of the operating environment inthe US and identify groups with relevant experience to support futureclinical trial activities. 

Overall, the weekreinforced our view that conditions are improving for teams that stay focusedand execute well. I left San Francisco encouraged by the opportunities ahead aswe continue to expand our engagement in the US market, with plenty to follow upon in the weeks and months ahead. 

On 21 January, Ananda's CEO, Melissa Sturgess, and CCO, Jack Morgan, gave a presentation on Ananda and what the year ahead has in store for the Company. For those who were unable to join live, we hope you enjoy the recording and slides available here.

‍

If you have any questions, please email ir@anandapharma.co.uk.